WuXi Biologics and Sartorius Stedim Biotech open joint laboratory in Shanghai

Opening of the Joint Laboratory in Shanghai

Certified leading upstream platform powers China’s biopharmaceutical development.

“As the upstream leader and pharmaceutical companies’ partner, Sartorius will strongly support the rapid expansion of the Chinese biopharmaceutical industry through ‘speed to clinic, increased titers, quality by design, and robust production," said Dr Joerg Lindenblatt, the Senior Vice President for Asia at Sartorius Stedim Biotech. "Cooperation between WuXi Biologics and Sartorius is based in China, but has a global perspective. Both parties share the same concepts on innovation and quality and have the same pursuit of global business development. I believe this Joint Laboratory will lay the foundation for sustainable development of both parties, accelerate the implementation of innovative technologies and solutions in a faster and broader way, and further benefit biopharmaceutical companies in the world.” "WuXi Biologics is devoted to building the leading ONE-stop service platforms for biologics R&D and manufacture and to providing comprehensive services for biopharmaceutical clients throughout the world,” said Dr Chris Chen, CEO of WuXi Biologics. “Collaboration with Sartorius is part of our effort to introduce innovative research concepts and world-leading technology platforms, which will shorten our time on biologics development, accelerate the biologics R&D process from concept to commercialization, lower the cost of biologics R&D and benefit patients around the world.” The Joint Laboratory is equipped with leading-edge single-use platforms including SSB's high-throughput ambr 15 and ambr 250, BIOSTAT STR single-use bioreactors and a single-use media/buffer preparation station. ambr is an automated, high-throughput microscale bioreactor system used by most of the international biopharmaceutical companies for their early stage R&D and process optimization, and supports accelerated development, optimization and rapid scale-up of cell culture processes.